Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a
malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of …

Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the
haemopoietic stem cell (HSC) compartment. This disease is characterised by a reciprocal t …

Purpose Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against
unmutated BCR-ABL in vitro. Phase II studies have demonstrated efficacy and safety with …

Background Although the vast majority of patients with chronic myeloid leukemia (CML)
respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate, resistance might occur de …

Stem cells are a relevant source of information about cellular differentiation, molecular
processes and tissue homeostasis, but also one of the most putative biological tools to treat …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …

Purpose There is substantial concern surrounding affordability of orally administered
anticancer therapies, particularly for Medicare beneficiaries. We examined rates of initiation …

A 28-year-old woman with recently diagnosed chronic myelogenous leukemia (CML)
presents for consideration of appropriate treatment. No siblings are available as candidate …

Background: The Philadelphia chromosome is formed from a translocation of genetic
material involving human chromosomes 9 and 22. The resulting gene product, BCR-ABL …

Treatments for chronic myeloid leukemia (CML) represent a success story in molecular
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …